Recent advances in partial cellular reprogramming using OSKM factors show promise in extending healthspan and treating age-related diseases, with biotech firms accelerating towards human trials. New r...
Recent studies show targeted epigenetic reprogramming with Yamanaka factors rejuvenates neurons, reversing cognitive decline in aged mice and reducing Alzheimer’s markers, with AI enhancing safe...
Analytical post exploring CAR-T cell therapy’s potential to treat Alzheimer’s by targeting amyloid plaques, with insights from recent clinical trials and cost-benefit considerations. Innov...
New research identifies IRF7 as a critical driver of unstable atherosclerotic plaques, offering a potential therapeutic target to reduce cardiovascular events through innovative clinical trials and te...
Recent studies reveal CAR-T cells with lecanemab antibodies reduce amyloid plaques in mice, highlighting a shift towards personalized cell-based therapies for Alzheimer’s treatment. New research...
A 2024 study in Nature Aging shows transferring young gut bacteria to aged mice rejuvenates intestinal stem cells via Wnt signaling, suggesting FMT’s potential for age-related disorders. Recent ...
A Nature Aging study shows mitochondrial stress enhances senolytic drugs like navitoclax, improving senescent cell removal by 40% with metabolic interventions. New research reveals mitochondrial stres...
The FDA has greenlit the first human trial of ER-100, a partial epigenetic reprogramming therapy targeting age-related eye diseases, marking a pivotal step in anti-aging and regenerative medicine. A l...
Emerging senolytic treatments target cellular senescence to reduce inflammation and improve kidney function in diabetic patients, with recent clinical trials confirming safety and hinting at efficacy....
Stanford Medicine study finds inhibiting 15-PGDH enzyme regenerates cartilage in aged mice, offering a non-invasive osteoarthritis treatment that could reduce joint replacements and improve life quali...
